Healthcare
Ginkgo Bioworks Holdings, Inc.(DNA)
Live Price
Offline$9.17
+7.25% today
1Y Change
-8.26%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $630.00M
- Revenue Growth
- -25.1%
- EPS Growth
- +46.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ginkgo Bioworks Holdings, Inc. (DNA) is a Healthcare stock with a market cap of $630.00M and listed on NYSE. The stock last traded around $9.17 and down 8.3% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of -25.1%, EPS growth of +46.5%, a dividend yield of 0.0%. What stands out right now is revenue -25.1%, EPS +46.5%, free cash flow +53.2% with operating margin -185.3% and ROIC -30.7%. Valuation is more restrained than many high-expectation growth names at price/sales 3.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DNA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-25.1% vs +7.6% peer median
Operating Margin
Below sector median
-185.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -25.1% and EPS is at +46.5%, with operating margin around -185.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -24.3% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +3.8% | -14.1% | -10.1% |
2026 Feb 26, 2026 | +21.1% | -30.5% | -29.6% | -34.0% |
2025 Nov 6, 2025 | -16.9% | -20.8% | -29.2% | -18.1% |
Benchmark Edge
DNA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DNA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DNA Max Drawdown
-66.05%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DNA and SPY.
Company Overview
Ginkgo Bioworks Holdings, Inc.
New York Stock Exchange
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
- Leadership
- Jason Kelly
- IPO Date
- Apr 19, 2021
- Employees
- 834
- Street Address
- 27 Drydock Avenue
- Mailing
- Boston, MA, 02210
- Region
- Boston, MA, US
- Reporting Currency
- USD
- Investor Line
- 877 422 5362
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 3.7
- Price/Book
- 1.1
Growth
- Revenue
- -25.1%
- EPS
- +46.5%
- Free Cash Flow
- +53.2%
Profitability
- Gross Margin
- 81.5%
- Operating Margin
- -185.3%
- Net Margin
- -183.8%
- ROE
- -53.7%
- ROIC
- -30.7%
Balance Sheet
- Debt/Equity
- 0.82
- Current Ratio
- 4.92
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.